Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of loncastuximab tesirine + rituximab versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
CTR20220246Phase 3Active
- Sponsor
- ADC Therapeutics
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of loncastuximab tesirine, rituximab, gemcitabine, oxaliplatin in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, sponsored by ADC Therapeutics. Started Jul 2022; status: active.
02
Drugs
loncastuximab tesirinerituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on CTR20220246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220246.